Drugs in ATC Class B01AB

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B01 - ANTITHROMBOTIC AGENTS

Up to B01A - ANTITHROMBOTIC AGENTS

Drugs in ATC Class: B01AB - Heparin group

Tradename	Generic Name
CALCIPARINE	heparin calcium
EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
HEPARIN LOCK FLUSH	heparin sodium
HEPARIN SODIUM	heparin sodium
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	heparin sodium
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	heparin sodium
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	heparin sodium

B01AB Market Analysis and Financial Projection

The heparin market (ATC Class B01AB) is experiencing steady growth driven by clinical demand and facing evolving patent dynamics. Here's a comprehensive analysis:

Market Dynamics

Current Valuation & Projections:

• 2023 baseline: $7.71B (SNS Insider) to $9.83B (Fortune Business Insights)
• 2030-2032 forecasts: $9.02B (IMARC) to $14.45B (Fortune)
• CAGR variations: 2.12% (IMARC) to 4.4% (Fortune) reflecting regional and product segmentation differences[1][3][9]

Key Growth Drivers:

1. Cardiovascular Disease Burden

   • 49M CVD patients in Europe, 4.58M annual CVD deaths in China (2020)[3][9]
   • 900K annual venous thromboembolism cases in the U.S.[9]

2. Surgical & Dialysis Demand
   Widely used for thromboprophylaxis in 62.4M annual inpatient surgeries in U.S. hospitals[3][6]

3. LMWH Adoption Low-molecular-weight heparins dominate with better pharmacokinetics:	Feature	Unfractionated Heparin	LMWH
   Half-life	1-2 hrs	4-7 hrs
   Monitoring	Required	Optional
   Dosing	IV/SC	SC-only

   Market shift driven by enoxaparin (B01AB05) and dalteparin (B01AB04)[4][10]

Regional Landscape:

• North America: 36%-51% market share (2023-24), led by Baxter/Pfizer[1][3]
• Asia-Pacific: Fastest growth (China's CVD deaths ↑48% 2005-2020)[3]
• Europe: Strict EMA oversight ensuring 98% therapy compliance[3]

Patent Landscape

Key Developments:

• LMWH Patent Expiries: Enoxaparin (Lovenox®) lost exclusivity, enabling biosimilars[4]
• Synthesis Innovations:
  • Biosynthetic heparin (US20190225998A1) avoids animal sourcing risks[12]
  • 62 active patents for LMWH characterization methods (2022 analysis)[4]

Regulatory Hurdles:

• FDA/EMA require 5-stage equivalence proof for biosimilars:
  1. Physicochemical properties
  2. Biological activity (anti-Xa/IIa ratio)
  3. Pharmacokinetic profile
  4. Clinical immunogenicity
  5. Post-marketing surveillance[4]

Market Challenges:

• Supply Chain Risks: 80% heparin sourced from porcine intestines - vulnerable to contamination[1][4]
• NOAC Competition: Direct oral anticoagulants capture 38% new prescriptions in EU[9]

Strategic Outlook

Emerging Opportunities:

1. Biosimilar Expansion: $1.2B potential in India/Brazil by 2027[9]
2. Specialty Heparins:
   • Heparinoids for topical use (ATC C05BA) growing at 3.8% CAGR[10]
   • Sulodexide (B01AB11) for diabetic nephropathy trials[10]

Key Players:

• Innovators: Sanofi, Pfizer, LEO Pharma (hold 57% LMWH patents)[4][6]
• API Suppliers: Shenzhen Hepalink (33% global heparin sodium supply)[3]

This market requires balancing biosynthetic innovation with cost-effective generics production, while navigating strict anticoagulation therapy guidelines and regional reimbursement policies.

References

1. https://www.fortunebusinessinsights.com/heparin-market-104447
2. https://go.drugbank.com/drugs/DB01109
3. https://www.imarcgroup.com/heparin-market
4. https://pubmed.ncbi.nlm.nih.gov/35915630/
5. https://aaltodoc.aalto.fi/bitstreams/79a80fd0-4ad7-4c1a-89ed-c768b830ac45/download
6. https://www.grandviewresearch.com/industry-analysis/heparin-market
7. https://prediction.charite.de/subpages/tree.php
8. https://www.businesswire.com/news/home/20250319568532/en/Humanoid-Robots-Research-Report-2025-A-$38-Billion-Market-Driven-by-Advances-in-AI-and-Autonomous-Systems---Technical-Advancements-Market-Dynamics-and-Potential-Across-Multiple-Verticals---ResearchAndMarkets.com
9. https://www.snsinsider.com/reports/heparin-market-2975
10. https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=B01AB
11. https://southeast.newschannelnebraska.com/story/52278471/global-labsa-market-dynamics-2025-unlocking-opportunities-through-2033
12. https://patents.google.com/patent/US20190225998A1/en